Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Current Leases (2019 - 2026)

Cogent Biosciences' Current Leases history spans 8 years, with the latest figure at $1.4 million for Q1 2026.

  • Quarterly Current Leases fell 14.15% to $1.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Mar 2026, down 14.15% year-over-year, with the annual reading at $1.5 million for FY2025, 1.15% down from the prior year.
  • Current Leases came in at $1.4 million for Q1 2026, down from $1.5 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $9.1 million in Q2 2022 to a low of $947000.0 in Q1 2023.
  • The 5-year median for Current Leases is $1.5 million (2024), against an average of $2.0 million.
  • Year-over-year, Current Leases surged 314.7% in 2022 and then plummeted 87.0% in 2023.
  • Cogent Biosciences' Current Leases stood at $1.4 million in 2022, then decreased by 2.6% to $1.4 million in 2023, then increased by 12.91% to $1.6 million in 2024, then dropped by 1.15% to $1.5 million in 2025, then decreased by 10.6% to $1.4 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Current Leases are $1.4 million (Q1 2026), $1.5 million (Q4 2025), and $1.7 million (Q3 2025).